 |
|
|
| |
Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449)
|
| |
| |
17thEuropean AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland
Reported by Jules Levin
F Maggiolo1, G Rizzardini2, JM Molina3, F Pulido4, S De Wit5, L Vandekerckhove6, J Berenguer7, C Blair8, S Chuck8, D Piontkowsky8, H Martin8, I McNicholl8, R Haubrich8,J Gallant8
1Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; 2Division of Infectious Diseases, Luigi Sacco Hospital, ASST FatebenefratelliSacco, Milan, Italy; 3Department of Infectious Diseases, Saint LouisHospital, University Paris Diderot, France; 4Unidad VIH, Hospital Universitario12 de Octubre, imas12, UCM, Madrid, Spain; 5St Pierre University Hospital, UniversiteLibrede Bruxelles, Brussels, Belgium; 6University Hospital Ghent, Belgium; 7Infectious Diseases, Hospital General UniversitarioGregorio Maranon(IiSGM), Madrid, Spain; 8Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
